Skip to Content

Gemzar (gemcitabine) Disease Interactions

There are 10 disease interactions with Gemzar (gemcitabine):

Major

Antineoplastics (Includes Gemzar) ↔ infections

Severe Potential Hazard, High plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  6. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  7. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  8. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  9. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  10. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  11. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  12. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  13. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  14. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  15. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  16. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  17. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  18. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  19. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  20. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  21. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  22. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  23. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  24. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
  25. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  26. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  27. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  28. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  29. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  30. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  31. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
View all 31 references
Major

Gemcitabine (Includes Gemzar) ↔ cardiovascular dysfunction

Severe Potential Hazard, Low plausibility. Applies to: Myocardial Infarction, Arrhythmias, Hypertension

Cardiovascular events such as myocardial infarction, arrhythmia, and hypertension have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with cardiovascular dysfunction.

References

  1. Carmichael J, Philip P, Rea D, Kerr H, Walling J, Harris AL, Possinger K "GEMCITABINE: AN ACTIVE DRUG IN ADVANCED BREAST CANCER. RESULTS OF A PHASE II STUDY (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 11 (1992): a1361992
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Gemcitabine (Includes Gemzar) ↔ hemolytic uremic syndrome

Severe Potential Hazard, Low plausibility. Applies to: Renal Dysfunction

Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis can occur in patients treated with gemcitabine. Renal function should be assessed prior to treatment initiation. Gemcitabine should be permanently discontinued in patients with HUS or severe renal impairment. Renal failure may not be reversible even with discontinuation of therapy.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Gemcitabine (Includes Gemzar) ↔ myelosuppression

Severe Potential Hazard, High plausibility. Applies to: Bone Marrow Depression/Low Blood Counts

Gemcitabine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during gemcitabine therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be administered cautiously and dosage modification considered in patients with bone marrow suppression. Close clinical monitory of hematopoietic function is recommended.

References

  1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study." J Clin Oncol 12 (1994): 1535-40
  2. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Gemcitabine (Includes Gemzar) ↔ cerebrovascular disease

Moderate Potential Hazard, Low plausibility. Applies to: Cerebral Vascular Disorder

Cerebrovascular accidents have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with known cerebrovascular disease.

References

  1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study." J Clin Oncol 12 (1994): 1535-40
  2. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Gemcitabine (Includes Gemzar) ↔ edema

Moderate Potential Hazard, High plausibility. Applies to: Fluid Retention

Edema has been reported frequently during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients adversely affected by fluid retention.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Gemcitabine (Includes Gemzar) ↔ hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Drug induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine for injection alone or in combination with other hepatotoxic drugs. Administration of gemcitabine in patients with concurrent liver metastases or preexisting medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of any underlying hepatic insufficiency. Hepatic function should be assessed prior to initiation of therapy and during treatment. The manufacturers state that no clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
Moderate

Gemcitabine (Includes Gemzar) ↔ paresthesia

Moderate Potential Hazard, Moderate plausibility. Applies to: Peripheral Neuropathy

Mild paresthesias and rare severe paresthesias have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with or predisposed to neurological dysfunction.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Gemcitabine (Includes Gemzar) ↔ pulmonary dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS) has been reported with the use of gemcitabine. In some cases, these pulmonary events can lead to fatal respiratory failure despite treatment discontinuation. Caution is advised if using in patients with history of pulmonary disease. Continuous monitoring of pulmonary function is advised.

Moderate

Gemcitabine (Includes Gemzar) ↔ renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No clinical studies have been conducted with gemcitabine in patients with decreased renal function. Caution is advised if used in these patients.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.

Gemzar (gemcitabine) drug interactions

There are 208 drug interactions with Gemzar (gemcitabine)

Gemzar (gemcitabine) alcohol/food interactions

There is 1 alcohol/food interaction with Gemzar (gemcitabine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide